A recent study published in the The Journal of Prevention of Alzheimer’s Disease provides detailed insight into clinicians’ and patients’ initial experience with lecanemab, the first Food and Drug Administration-approved antiamyloid monoclonal antibody infusion proven to slow cognitive and functional decline due to Alzheimer’s disease. Conducted at the Norton Neuroscience Institute Memory Center, the study…
A world-renowned diabetes researcher has joined Wendy Novak Diabetes Institute, a part of Norton Healthcare and Norton Children’s, with the goal of curing Type 1 diabetes. Balamurugan N. Appakalai, Ph.D., also known as Dr. Bala, is a leading researcher in islet cell transplants and is widely considered one of the most skilled islet isolation specialists…
Clinical research, including clinical trials, is a crucial component to advancing the discovery of cancer therapeutics. Norton Cancer Institute contributes to this advancement through participation in numerous clinical trials every year. 4 phases of clinical trial There are four phases in a clinical trial, each with a different purpose. This helps researchers answer different questions…
Norton Research Institute will expand research efforts with the unveiling of the new Norton Research Institute Clinical & Translational Research Laboratory. The 7,200-square-foot facility, located inside Norton Healthcare Pavilion in downtown Louisville, will afford ample space and resources for scientists to conduct cutting-edge research, with the goal of producing more meaningful, applicable results directly benefiting patient…
Robot-assisted sacroiliac joint (SIJ) fusion surgery can, in about 1% of cases, injure the superior gluteal artery (SGA), but preoperative imaging, precise robot-assisted screw insertion and soft tissue protection can mitigate risks, according to a recently published study in the Journal of Neurosurgery: Case Lessons. The study describes the case of an 80-year-old man who…
Safer controlled substance prescribing begins with a thorough patient workup, an appropriate diagnosis and a comprehensive treatment plan, according to Kelly C. Cooper, M.D., an addiction medicine specialist with Norton Behavioral Medicine. “We just tend to go for the pills first. And it’s not just as providers, it’s patients as well,” Dr. Cooper said during…
Artificial intelligence (AI) like ChatGPT can compose essays or emails, write computer code, even generate art, but how well can it manage complex patient care? A team that included Norton Healthcare researchers decided to find out. They compared ChatGPT’s recommendations for managing an 81-year-old patient with nonresolving pneumonia with those of a pulmonary specialist. “What…
Patients 18 years of age and older with cystic fibrosis now have an option of participating in a Phase 1 trial of a novel, broad-spectrum, orally delivered enzyme replacement therapy for cystic fibrosis (CF). The randomized, active-treatment trial is testing the safety, tolerability and effect of four dose levels of ANG003, a compound developed by…
Norton Healthcare has launched a new, open-access medical journal to promote the sharing of innovation and ideas from the laboratory, the bedside and everyday practice. Norton Healthcare Medical Journal welcomes original articles related to medicine, nursing, public health, pharmacy and dentistry, across the full continuum of health care for adult and pediatric populations. The no-cost-to-publish,…
Louisville Business First has recognized researchers at Norton Healthcare with its 2024 Health Care Heroes Innovator Award. The award honors those who break ground in the health care field by developing or implementing new technology, treatments or programs with wide applications. Award recipients were: Manager Award This award honors leaders ranging from the head of a small…
Butyrate-producing gut bacteria are a promising target for preventing and treating memory loss associated with Alzheimer’s disease, according to research presented recently at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. The research in 3XTg mouse model demonstrated that oral administration of tributyrin mitigates age-associated loss of butyrate-producing bacteria and prevents the decline in…
A human Phase 1 immunotherapy clinical trial is underway using natural killer cells, or NK cells, to target relapsed or refractory acute myeloid leukemia. Acute myeloid leukemia patients who have exhausted other treatment options are potential candidates for the trial, ClinicalTrials.gov ID NCT05470140. The trial uses cytokine-reprogrammed, non-engineered, “off-the-shelf” NK cells from a healthy donor….